NASDAQ: SONN - Sonnet BioTherapeutics Holdings, Inc.

Yield per half year: -80.42%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Sonnet BioTherapeutics Holdings, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial.

more details
The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2006-10-31
ISIN US83548R2040
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.sonnetbio.com
Цена ао 1.33
Change price per day: 0% (1.31)
Change price per week: -5.07% (1.38)
Change price per month: -13.82% (1.52)
Change price per 3 month: -13.25% (1.51)
Change price per half year: -80.42% (6.69)
Change price per year: -29.57% (1.86)
Change price per 3 year: +220.29% (0.409)
Change price per 5 year: +236.07% (0.3898)
Change price per year to date: -23.84% (1.72)
All parameters

Underestimation

Title Value Grade
P/S 235.35 1
P/BV -9.02 0
P/E 0 0
EV/EBITDA -0.3684 0
Total: 2.75

Efficiency

Title Value Grade
ROA, % -181.38 0
ROE, % 2089.93 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.011 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -99.94 0
Yield Ebitda, % 12.85 2
Yield EPS, % -75.41 0
Total: 0.4
More

Institutions Volume Share, %
Renaissance Technologies, LLC 43749 1.43
Citadel Advisors Llc 29447 0.96
Vanguard Group Inc 14726 0.48
Tower Research Capital LLC (TRC) 2094 0.07
Blackrock Inc. 594 0.02
Morgan Stanley 61 0
Osaic Holdings Inc 45 0
Wells Fargo & Company 21 0
JP Morgan Chase & Company 19 0
Private Wealth Management Group, LLC 3 0



Head Job title Payment Year of birth
Dr. Pankaj Mohan Ph.D. Founder, Chairman, CEO & President 927k 1965 (60 years)
Dr. John K. Cini Ph.D. Chief Scientific Officer & Co-Founder 602.48k 1953 (72 years)
Mr. Jay Cross Chief Financial Officer 603.42k 1971 (54 years)
Mr. Donald J. Griffith CPA, CPA Controller & Director 134.05k 1949 (76 years)
Ms. Susan Dexter Chief Technical Officer N/A 1955 (70 years)
Dr. Richard T. Kenney FACP, M.D. Chief Medical Officer N/A 1958 (67 years)
Mr. Manuel Dafonseca Head of Clinical Operations N/A

Address: United States, Princeton. NJ, 100 Overlook Center - open in Google maps, open in Yandex maps
Website: https://www.sonnetbio.com